While ECT may be considered for moderate depression in certain cases, it should not be administered if it goes against a legally binding advance decision of directive.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

Prevention measures can be classified into different levels, depending on the stage at which they are implemented. The first model, developed in the 1960s, includes primary, secondary, and tertiary prevention. Primary prevention aims to intervene before a disease of problem begins, and can be universal (targeted to the general public), selective (targeted to a high-risk population), of indicated (targeted to individuals with minimal but detectable signs of a disorder). Secondary prevention aims to detect and treat disease that has not yet become symptomatic, while tertiary prevention involves the care of established disease.

A newer model, developed in 1992, focuses on prevention interventions used before the initial onset of a disorder. This model also includes three levels: universal prevention (targeted to the general population), selective prevention (targeted to a high-risk population), and indicated prevention (targeted to individuals with minimal but detectable signs of a disorder). Examples of prevention measures include cognitive interventions for adolescents with cognitive deficits to prevent the later phases of schizophrenia, screening procedures for early detection and treatment of disease, and the use of low-dose atypical antipsychotics and CBT for patients with prodromal symptoms of schizophrenia to delay of prevent disease onset.

The Care Program Approach (CPA) was implemented in 1991 to enhance community care for individuals with severe mental illness. The CPA comprises four primary components, including assessment, a care plan, a Care Coordinator (formerly known as a Key Worker), and regular review. There are two levels of CPA, namely standard and enhanced. Standard care plans are suitable for individuals who require minimal input from a single agency and pose minimal risk to themselves of others. Enhanced care plans are designed for individuals with complex needs who require collaboration among multiple agencies.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

The advancements in technology and the widespread availability of smartphones and internet access can be utilized to improve patient care and equip clinicians with more tools for diagnosing and treating mental illnesses. One promising approach is avatar therapy, which has shown positive results in treating auditory hallucinations in patients who did not respond well to medication. Additionally, automated objective behavioral analysis has been used to monitor and predict mood and emotional responses. However, online cognitive behavioral therapy has not been found to be effective in treating auditory hallucinations. Personal Zen is a mobile and tablet app that gamifies techniques proven to be helpful in managing anxiety and stress. Finally, virtual reality exposure therapy has been used to treat post-traumatic stress disorder.

In ECT, a seizure lasting more than 120 seconds is considered prolonged and can be stopped with intravenous diazepam. While there is no clear link between treatment success and seizure duration, it is advised to adjust the electricity dose to achieve a seizure lasting between 20 and 50 seconds. Short seizures may not be effective, while longer seizures may lead to cognitive issues.

If a patient’s plasma clozapine to norclozapine ratio decreases while on a consistent clozapine dose, it may indicate enzyme induction. Conversely, an increase in the ratio may suggest enzyme inhibition of saturation, recent non-trough sample, of poor compliance. The clozapine to norclozapine ratio is typically stable among patients with stable clozapine doses.

The recovery model raises questions about how to define recovery from a mental health problem. Mental health services tend to define recovery based on measures such as symptom remission, hospitalization, independence, and involvement in work of school. However, people with mental health problems define recovery differently, placing importance on factors such as overcoming the effects of being a patient, establishing a fulfilling life and positive identity, and discovering how to live well with enduring symptoms.

Gillick Competency and Fraser Guidelines

Gillick competency and Fraser guidelines refer to a legal case which looked specifically at whether doctors should be able to give contraceptive advice of treatment to under 16-year-olds without parental consent. But since then, they have been more widely used to help assess whether a child has the maturity to make their own decisions and to understand the implications of those decisions.

In 1982, Mrs Victoria Gillick took her local health authority (West Norfolk and Wisbech Area Health Authority) and the Department of Health and Social Security to court in an attempt to stop doctors from giving contraceptive advice of treatment to under 16-year-olds without parental consent.

The case went to the High Court where Mr Justice Woolf dismissed Mrs Gillick’s claims. The Court of Appeal reversed this decision, but in 1985 it went to the House of Lords and the Law Lords (Lord Scarman, Lord Fraser and Lord Bridge) ruled in favour of the original judgement delivered by Mr Justice Woolf.

The Fraser Guidelines were laid down by Lord Fraser in the House of Lords’ case and state that it is lawful for doctors to provide contraceptive advice and treatment without parental consent providing that they are satisfied that:

– The young person will understand the professional’s advice
– The young person cannot be persuaded to inform their parents
– The young person is likely to begin, of to continue having, sexual intercourse with of without contraceptive treatment
– Unless the young person receives contraceptive treatment, their physical of mental health, of both, are likely to suffer
– The young person’s best interests require them to receive contraceptive advice of treatment with of without parental consent.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

Neurostimulation is a treatment that uses electromagnetic energy targeted at the brain. There are several forms of neurostimulation, including TMS, deep brain stimulation, and ECT. TMS is a non-invasive, non-convulsive technique used to stimulate neural tissue. It involves the placement of an electromagnetic coil on the patient’s scalp to deliver a short, powerful magnetic field pulse through the scalp and induce electric current in the brain. TMS is used to treat depression when standard treatments have failed. Deep brain stimulation is a neurosurgical technique that involves placing an electrode within the brain to deliver a high-frequency current in a specific subcortical of deep cortical structure. It has been used to treat Parkinson’s, dysthymia, OCD, and Tourette syndrome. There is RCT evidence to demonstrate its effectiveness in OCD, but conflicting results in depression and Tourette’s. DBS is also being trailed in other conditions such as anorexia, bipolar, and additions.

DBS, a type of neurosurgery, is typically conducted in an operating theatre and has been shown to be effective in treating OCD based on randomized controlled trial (RCT) data. However, there are currently no NICE Guidelines available for DBS.

Neurostimulation is a treatment that uses electromagnetic energy targeted at the brain. There are several forms of neurostimulation, including TMS, deep brain stimulation, and ECT. TMS is a non-invasive, non-convulsive technique used to stimulate neural tissue. It involves the placement of an electromagnetic coil on the patient’s scalp to deliver a short, powerful magnetic field pulse through the scalp and induce electric current in the brain. TMS is used to treat depression when standard treatments have failed. Deep brain stimulation is a neurosurgical technique that involves placing an electrode within the brain to deliver a high-frequency current in a specific subcortical of deep cortical structure. It has been used to treat Parkinson’s, dysthymia, OCD, and Tourette syndrome. There is RCT evidence to demonstrate its effectiveness in OCD, but conflicting results in depression and Tourette’s. DBS is also being trailed in other conditions such as anorexia, bipolar, and additions.

DBS can lead to various complications, such as intracranial bleeding (which occurs in around 2.0-2.5% of implants), dislocation, lead fracture, and infection. Additionally, stimulation-induced adverse side effects may include paraesthesia, tonic muscle contractions, dyskinesia, and gait ataxia. While less common, some individuals may experience side effects such as aggression, mirthful laughter, depression, penile erection, of mania.

The typical location for the implanted pulse generator (IPG) in DBS treatment is subcutaneously below the clavicle, which is similar to where cardiac pacemakers are placed. While IPGs are sometimes placed abdominally, it is less common. Peripherally inserted central catheter (PICC) lines are usually located in the antecubital fossa, and external microphones for cochlear implants are implanted in the temporal bone. Cardiac pacemakers may be placed in the axilla.

The human cortex was first directly stimulated in 1874, followed by the use of frontal tract stimulation for chronic pain in 1948. Thalamic stimulation for tremor was introduced in 1960, and basal ganglia stimulation for Parkinson’s tremor in 1968. The effectiveness of stimulation in treating epilepsy was discovered in 1973, and for depression in 1987.

A randomized control trial conducted by Prakash demonstrated that the memory enhancing drug, donepezil hydrochloride, can decrease the time required for recovery after undergoing ECT. This finding suggests that donepezil may have therapeutic and prophylactic benefits for patients undergoing ECT. The study was published in the Journal of ECT in 2006.

ECT and Seizure Duration: Effect of Psychotropics

On the whole, most drugs do not interfere with ECT. However, it is important to note the effect of psychotropics on seizure duration. The table below summarizes the effect of important psychotropics and their advice:

Psychotropic class: Benzodiazepine
Effect on seizure duration: Reduced
Advice: Avoid where possible

Psychotropic class: SSRIs
Effect on seizure duration: Minimal effect

Psychotropic class: Venlafaxine
Effect on seizure duration: Minimal effect

Psychotropic class: TCAs
Effect on seizure duration: Possibly increased
Advice: TCAs are associated with arrhythmia following ECT in the elderly and those with cardiac disease, so they should be avoided in ECT in these groups.

Psychotropic class: MAOIs
Effect on seizure duration: Minimal effect

Psychotropic class: Lithium
Effect on seizure duration: Possibly increased
Advice: Generally used in ECT without significant problems.

Psychotropic class: Antipsychotics
Effect on seizure duration: Some potential increase in clozapine and phenothiazines, other antipsychotics considered ok
Advice: Limited data.

Psychotropic class: Anticonvulsants
Effect on seizure duration: Reduced
Advice: If used as a mood stabilizer, continue but be prepared to use higher energy stimulus.

(Source: Maudsley Guidelines 10th Edition, p.187)

Out of the population aged 16 of over, 19% do not consume alcohol, while 60% have a low risk pattern of alcohol consumption. 17% have an increased risk pattern, and 4% have a higher risk pattern, according to the classification of alcohol consumption based on weekly units.

Research has consistently shown that out-patient services, whether they are general of specialized eating disorder clinics, are more likely to be cost-effective than in-patient care. The majority of patients with eating disorders can be effectively managed in out-patient clinics, with only a small percentage requiring in-patient care. When comparing outpatient treatment models, including general child and adolescent mental health services, with in-patient treatment, there were significant improvements in all groups at different points during follow-up, with no significant differences between the two types of treatment. The availability of out-patient care is associated with a lower rate of admission to inpatient units. Clinically and economically, lengthy in-patient stays are not recommended, as they are associated with worse outcomes, particularly when they disrupt the patient’s life, such as their work, studies, of time away from family.

Given the patient’s improved psychotic symptoms, an extended stay in an acute ward would not be beneficial. However, due to ongoing substance misuse and challenging behaviors, discharge from the hospital is not yet possible. While an addictions admission of transfer to a forensic ward is not necessary, a rehabilitation psychiatry ward would be the most appropriate next step. This would provide the patient with the necessary support to address their substance misuse and challenging behaviors, while also promoting their skills and independence for a successful return to community living.

Challenges and Benefits of Service User Involvement

Paragraph 1: Implementing service user involvement can be costly and time-consuming for both organisations and service users. However, if done properly, it can bring significant benefits.

Paragraph 2: In the past, there has been resistance to the idea of using service users as experts. However, involving service users in decision-making processes can lead to more effective and relevant services.

Paragraph 3: Contrary to popular belief, service user involvement can actually help overcome social isolation and improve mental health outcomes.

Paragraph 4: Despite the benefits, there has historically been a lack of resources for service users and carers on how to get involved in their local services. This needs to be addressed to ensure that service user involvement is accessible and inclusive.

If there is a dispute regarding the recent diagnosis, it would be best for the patient to seek a second opinion assessment. During this time, it is recommended that the patient refrains from driving. It is the responsibility of the license holder to inform the DVLA of any changes in their medical condition that may affect their ability to drive safely. Patients should be informed of any conditions that may impact their driving ability and their legal obligation to inform the DVLA. The GMC has provided clear guidance for situations where a license holder is unwilling or unable to inform the DVLA. If a doctor is unable to convince a patient to stop driving of discovers that the patient is driving against their advice, they should immediately contact the DVLA and provide any relevant information in confidence to the medical adviser. Before contacting the DVLA, the patient should be advised and informed in writing after contact has been made. It is not appropriate to breach confidentiality by speaking to the patient’s family without their consent.

In May 2014, the UK implemented a ban on selling alcohol below the cost of duty and VAT, known as below-cost selling. According to researchers at the University of Sheffield, this ban is expected to result in the prevention of 14 deaths and 500 hospital admissions each year in England.

Principles of Prevention for Depression

Depression can be prevented through various principles of prevention. According to an article on depression prevention, there are different levels of prevention that aim to reduce the incidence, prevalence, and associated disability of depression.

Primary prevention focuses on reducing the occurrence of depression in the general population. This can be achieved through public health campaigns, education, and awareness programs.

Secondary prevention targets subgroups of the population who are identified as at risk for depression. This can include individuals with a family history of depression, those who have experienced traumatic events, of those with chronic illnesses.

Tertiary prevention aims to reduce the disability associated with depression. This can involve providing support and treatment to individuals who have already developed depression, in order to prevent further complications and improve their quality of life.

Universal prevention targets the entire population, while selective prevention targets specific subgroups. Indicated prevention targets individuals who are at a prodromal stage of depression, meaning they are showing early signs of the illness.

By implementing these principles of prevention, it is possible to reduce the incidence, prevalence, and disability associated with depression.

Institutional Racism in Psychiatry

There has been growing concern that institutional racism may be contributing to the overrepresentation of Black patients in mental health settings. Despite ethnic minorities making up only 9% of the UK population, the 2010 ‘Count me in Census’ found that 23% of inpatients and those on CTOs were from Black and minority ethnic groups. Black minority groups also had higher rates of admission, detention, and seclusion.

While patient factors, such as higher rates of mental illness in Black minority groups, may contribute to these findings, there is also a suggestion of inherent racism within psychiatry. This may manifest in perceptions of Black and minority ethnic patients being at greater risk, as well as systemic factors that disadvantage these groups.

It is important to address these issues and work towards a more equitable and just mental health system for all patients, regardless of their ethnicity.

Electroconvulsive therapy (ECT) is known to cause retrograde amnesia, which is the most persistent cognitive side effect (Lisanby, 2000). Patients often experience memory gaps for events that occurred around the time of ECT, and sometimes even for events that happened months of years prior. While retrograde amnesia typically improves within a few months after treatment, some patients may not fully recover and may have permanent memory loss for events close to the time of treatment. Additionally, anterograde amnesia may also be a possible side effect.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

Gillick Competency and Fraser Guidelines

Gillick competency and Fraser guidelines refer to a legal case which looked specifically at whether doctors should be able to give contraceptive advice of treatment to under 16-year-olds without parental consent. But since then, they have been more widely used to help assess whether a child has the maturity to make their own decisions and to understand the implications of those decisions.

In 1982, Mrs Victoria Gillick took her local health authority (West Norfolk and Wisbech Area Health Authority) and the Department of Health and Social Security to court in an attempt to stop doctors from giving contraceptive advice of treatment to under 16-year-olds without parental consent.

The case went to the High Court where Mr Justice Woolf dismissed Mrs Gillick’s claims. The Court of Appeal reversed this decision, but in 1985 it went to the House of Lords and the Law Lords (Lord Scarman, Lord Fraser and Lord Bridge) ruled in favour of the original judgement delivered by Mr Justice Woolf.

The Fraser Guidelines were laid down by Lord Fraser in the House of Lords’ case and state that it is lawful for doctors to provide contraceptive advice and treatment without parental consent providing that they are satisfied that:

– The young person will understand the professional’s advice
– The young person cannot be persuaded to inform their parents
– The young person is likely to begin, of to continue having, sexual intercourse with of without contraceptive treatment
– Unless the young person receives contraceptive treatment, their physical of mental health, of both, are likely to suffer
– The young person’s best interests require them to receive contraceptive advice of treatment with of without parental consent.

ECT and Seizure Duration: Effect of Psychotropics

On the whole, most drugs do not interfere with ECT. However, it is important to note the effect of psychotropics on seizure duration. The table below summarizes the effect of important psychotropics and their advice:

Psychotropic class: Benzodiazepine
Effect on seizure duration: Reduced
Advice: Avoid where possible

Psychotropic class: SSRIs
Effect on seizure duration: Minimal effect

Psychotropic class: Venlafaxine
Effect on seizure duration: Minimal effect

Psychotropic class: TCAs
Effect on seizure duration: Possibly increased
Advice: TCAs are associated with arrhythmia following ECT in the elderly and those with cardiac disease, so they should be avoided in ECT in these groups.

Psychotropic class: MAOIs
Effect on seizure duration: Minimal effect

Psychotropic class: Lithium
Effect on seizure duration: Possibly increased
Advice: Generally used in ECT without significant problems.

Psychotropic class: Antipsychotics
Effect on seizure duration: Some potential increase in clozapine and phenothiazines, other antipsychotics considered ok
Advice: Limited data.

Psychotropic class: Anticonvulsants
Effect on seizure duration: Reduced
Advice: If used as a mood stabilizer, continue but be prepared to use higher energy stimulus.

(Source: Maudsley Guidelines 10th Edition, p.187)

Preventative Treatment Options for Psychosis

According to NICE guidelines, individual cognitive-behavioral therapy (CBT) is a recommended preventative treatment option for individuals at high risk of developing psychosis, with of without family intervention. However, antipsychotic medication is not recommended for preventing of reducing the risk of psychosis. Dialectic behavior therapy (DBT) is typically used for patients with borderline personality disorder, while omega 3 fatty acids have shown some potential in treating refractory schizophrenia. Psychodynamic psychotherapy is generally not recommended for possible early onset psychosis.

The ECTAS Guidelines 2019 recommend a frequency of two times per week.

ECT (Treatment) – Summary of Effectiveness and Recommendations

ECT (Electroconvulsive Therapy) is a treatment that induces a therapeutic seizure through the application of electrical current under general anesthesia and muscle relaxation. It is prescribed as a course and is usually administered twice weekly for 6 to 12 treatments. ECT is the most effective short-term treatment for major depression, with remission rates of around 60-80% when used as first-line treatment in a severe depressive episode. However, without maintenance treatment, the relapse rate is extremely high (over 80%) in the 6 months after successful ECT.

Cognitive effects are the main limitation to the wider use of ECT, particularly acute confusion shortly after the treatment, retrograde amnesia, and some losses in autobiographical memory longer term. The current state of evidence does not allow the general use of ECT in the management of schizophrenia. Bilateral ECT is more effective than unilateral ECT but may cause more cognitive impairment. With unilateral ECT, a higher stimulus dose is associated with greater efficacy but also increased cognitive impairment compared with a lower stimulus dose.

NICE (National Institute for Health and Care Excellence) recommends that ECT is used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/of when the condition is considered to be potentially life-threatening. ECT is recommended for individuals with severe depression (that is life-threatening and when a rapid response is required, of when other treatments have failed), moderate depression (consider it if their depression has not responded to multiple drug treatments and psychological treatment), catatonia, and a prolonged of severe manic episode.

The RCPsych (Royal College of Psychiatrists) position on ECT recommends it as a first-line treatment for individuals with high suicidal risk, severe psychomotor retardation and associated problems of compromised eating and drinking and/of physical deterioration, treatment-resistant depression that has responded to ECT in a previous episode of illness, pregnant individuals with severe depression, of severe mixed affective states, mania of catatonia and whose physical health of that of the fetus is at serious risk, and those who prefer this form of treatment. ECT is recommended as a second-line treatment for individuals with treatment-resistant depression, severe side-effects from medication, and persistent of life-threatening symptoms in severe of prolonged mania. ECT is indicated in some circumstances for individuals with bipolar depression, postnatal psychosis, treatment-resistant schizophrenia, treatment-resistant catatonia, and frequent relapses and recurrences of depression (maintenance).

In patients who received right unilateral ECT, it was found through univariate analyses that a higher seizure threshold was linked to advanced age, male gender, a greater burden of medical illness, weight, longer duration of mood disorder, and a history of previous ECT. However, the average lorazepam dose taken in the 48 hours before ECT did not have a correlation with seizure threshold, but it was associated with a reduction in seizure duration.